



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
-----------------	-------------	----------------------	---------------------

09/105,238 02/17/92 NOLAN

G A-05635-1/DJ

EXAMINER

HM12/0621

FLEHR HUBBACH TEST
ALBRITTON & HERBERT
4 EMBARCADERO CENTER SUITE 0400
SAN FRANCISCO CA 94111

SHUKLA, R

ART UNIT

PAPER NUMBER

1632

DATE MAILED:

06/21/00

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

File A-05635-1 Atty DJB, RMS, SDR

Due Date 7/21/2000

Type 1mo Resp Refs re
re: omission
correction



App

UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
09/135,238	08-17-98	NOLAN GP	

DAVID BREZNER
FLEHR HOHBACH TEST ALBRITTON & HERBERT LLP
FOUR EMBARCADERO CENTER, SUITE 3400
SAN FRANCISCO, CALIFORNIA 94111-4187

EXAMINER	
Ram R. Shukla, Ph.D.	
ART UNIT	PAPER NUMBER
1632	12

DATE MAILED:

Please find below a communication from the EXAMINER in charge of this application.

Commissioner of Patents

The reply filed 5-17-00 is not fully responsive to the communication mailed 10-21-99 for the reason(s) set forth on the attached Notice To Comply With The Sequence Rules or CRF Diskette Problem Report and for the following reasons.

Amendments filed in the above response are to another application, not to the instant application.

Since the above-mentioned reply appears to be *bona fide*, applicant is given a TIME PERIOD of **ONE (1) MONTH or THIRTY (30) DAYS**, from the mailing date of this notice, whichever is longer, within which to supply the omission or correction in order to avoid abandonment. EXTENSIONS OF THIS TIME LIMIT MAY BE GRANTED UNDER 37 CFR 1.136(a).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ram R. Shukla whose telephone number is (703) 305-1677. The examiner can normally be reached on Monday through Thursday and every other Friday from 8:00 am to 5:30 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jasmine Chambers, can be reached on (703) 308-2035. The fax phone number for this Group is (703) 308-4242.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 305-0196.

Ram R. Shukla, Ph.D.

Jasmine C. Chambers
JASEMINE CHAMBERS
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/ AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s):

JUL 24 2000
PATENT & TRADEMARK OFFICE

- ☐ 1. This application clearly fails to comply with the requirements of 37 CFR 1.821 - 1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
 - ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).
 - ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
 - ☒ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."
 - ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
 - ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).
 - ☒ 7. *Amendment does not belong to this application.*
- Other: _____

Applicant must provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing"
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d)

For questions regarding compliance with these requirements, please contact:

For Rules Interpretation, call (703) 308-1123
For CRF submission help, call (703) 308-4212
For PatentIn software help, call (703) 557-0400

Please return a copy of this notice with your response.

Raw Sequence Listing Error Summary

ERROR DETECTED SUGGESTED CORRECTION

JUL 24 2000

SERIAL NUMBER:

09/135,238A

ATTN: NEW RULES CASES: PLEASE DISREGARD ENGLISH "ALPHA" HEADERS, WHICH WERE INSERTED BY PTO SOFTWARE

- 1 Wrapped Nucleics The number/text at the end of each line "wrapped" down to the next line.
This may occur if your file was retrieved in a word processor after creating it.
Please adjust your right margin to .3, as this will prevent "wrapping".
- 2 Wrapped Aminos The amino acid number/text at the end of each line "wrapped " down to the next line.
This may occur if your file was retrieved in a word processor after creating it.
Please adjust your right margin to .3, as this will prevent "wrapping".
- 3 Incorrect Line Length The rules require that a line not exceed 72 characters in length. This includes spaces.
- 4 Misaligned Amino Acid The numbering under each 5th amino acid is misaligned. This may be caused by the use of tabs
Numbering between the numbering. It is recommended to delete any tabs and use spacing between the numbers.
- 5 Non-ASCII This file was not saved in ASCII (DOS) text, as required by the Sequence Rules.
Please ensure your subsequent submission is saved in ASCII text so that it can be processed.
- 3 Variable Length Sequence(s) contain n's or Xaa's which represented more than one residue.
As per the rules, each n or Xaa can only represent a single residue.
Please present the maximum number of each residue having variable length and
indicate in the (ix) feature section that some may be missing.
- 7 PatentIn ver. 2.0 "bug" A "bug" in PatentIn version 2.0 has caused the <220>-<223> section to be missing from amino acid
sequence(s) . Normally, PatentIn would automatically generate this section from the
previously coded nucleic acid sequence. Please manually copy the relevant <220>-<223> section
to the subsequent amino acid sequence.
- 3 Skipped Sequences Sequence(s) missing. If intentional, please use the following format for each skipped sequence:
(OLD RULES) (2) INFORMATION FOR SEQ ID NO:X:
 (1) SEQUENCE CHARACTERISTICS:(Do not insert any headings under "SEQUENCE CHARACTERISTICS")
 (xi) SEQUENCE DESCRIPTION:SEQ ID NO:X:
 This sequence is intentionally skipped

Please also adjust the "(iii) NUMBER OF SEQUENCES:" response to include the skipped sequence(s).
- 3 Skipped Sequences Sequence(s) missing. If intentional, please use the following format for each skipped sequence.
(NEW RULES) <210> sequence id number
 <400> sequence id number
 000
- 1 Use of n's or Xaa's Use of n's and/or Xaa's have been detected in the Sequence Listing.
(NEW RULES) Use of <220> to <223> is MANDATORY if n's or Xaa's are present.
In <220> to <223> section, please explain location of n or Xaa, and which residue n or Xaa represents.
- 1 Use of <213>Organism Sequence(s) are missing this mandatory field or its response.
(NEW RULES)
- 2 Use of <220>Feature Sequence(s) are missing the <220>Feature and associated headings.
(NEW RULES) Use of <220> to <223> is MANDATORY if <213>ORGANISM is "Artificial" or "Unknown"
Please explain source of genetic material in <220> to <223> section.
(See "Federal Register," 6/01/98, Vol. 63, No. 104, pp. 29631-32) (Sec. 1.823 of new Rules)
- 1 PatentIn ver. 2.0 "bug" Please do not use "C py to Disk" function of PatentIn version 2.0. This causes a corrupted
file, resulting in missing mandatory numeric identifiers and responses (as indicated on raw sequence listing).
Instead, please use "File Manager" or any other means to copy file to floppy disk.

AKS-Biotechnology Systems Branch- 5/15/99

R. Shukla

1632

PAGE: 1

RAW SEQUENCE LISTING
PATENT APPLICATION US/09/135,238ADATE: 12/15/1999
TIME: 12:57:29

Input Set: I135238A.RAW

This Raw Listing contains the General Information
Section and up to first 5 pages.

1 <110> APPLICANT: Nolan, Garry P.
2 Hitoshi, Yasumichi
3 <120> TITLE OF INVENTION: TOSO
4 <130> FILE REFERENCE: A65635-1/DJB/RMS
5 <140> CURRENT APPLICATION NUMBER: US/09/135,238A
6 <141> CURRENT FILING DATE: 1998-08-17
7 <150> EARLIER APPLICATION NUMBER: 06/066,063
8 <151> EARLIER FILING DATE: 1997-11-17
9 <160> NUMBER OF SEQ ID NOS: 31
10 <170> SOFTWARE: PatentIn Ver. 2.0
11 <210> SEQ ID NO 1
12 <211> LENGTH: 1910
13 <212> TYPE: DNA
14 <213> ORGANISM: Homo sapiens
15 <400> SEQUENCE: 1
16 aaaggagtaa gcagcgtgtc tccatccccc tctctagggg ctcttggatg gaccttgca 60
17 tctagaaggg acaatggact tctggttttg gccactttac ttcctgccag tatcaggggc 120
18 cctgaggatc ctcccagaag taaaggtaga gggggagctg ggccgatcag ttaccatcaa 180
19 atgcccactt cctgaaatgc atgtgaggat atatctgtgc cgggagatgg ctggatctgg 240
20 aacatgtggt accgtggtat ccaccaccaa cttcatcaag gcagaataca agggccgagt 300
21 tactctgaag caatacccac gcaagaatct gttcctagtg gaggtaacac agctgacaga 360
22 aagtgcacgc ggagtctatg cctgcggagc gggcatgaac acagaccggg gaaagaccca 420
23 gaaagtcacc ctgaatgtcc acagtgaata cgagccatca tgggaagagc agccaatgcc 480
24 tgagactcca aaatggttcc atctgcccta tttgttccag atgcctgcat atgccagttc 540
25 ttccaaattc gtaaccagag ttaccacacc agtcaaaagg ggcaagggtc cttcagttca 600
26 ccactctctc cccaccaccc aaatcaccca ccgccctcga gtgtccagag catcttcagt 660
27 agcaggtgac aagccccgaa ccttccctgcc atccactaca gcctcaaaaa tctcagctct 720
28 ggaggggctg ctcaagcccc agacgccag ctacaaccac cacaccaggc tgcacaggca 780
29 gagagcatcg gactatggct cacagtctgg gaggggaagg caaggatttc acatcctgat 840
30 cccgaccatc ctgggccttt tctgtctggc acttctgggg ctggtggtga aaagggccgt 900
31 tgaaaggagg aaagccctct ccaggcgggc ccgccgactg gccgtgagga tgcgcgccct 960
32 ggagagctcc cagaggcccc gcgggtcgcc gcgaccgcgc tcccaaaaca acatctacag 1020
33 cgctgccccg cggcgcgctc tggagcggac gctgcaggca caggggaggc ccccgttccc 1080
34 ggcgccggag cgccgttgcc ccccgccccg ctgcagggtg ctgaatctcc ctggctccat 1140
35 gccccatctc tgaagaccag ctgtgaatac gtgagcctct accaccagcc tgccgccatg 1200
36 atggaggaca gtgattcaga tgactacatc aatgttctct cctgacaact cccagctat 1260
37 cccccaaccc caggctcgga ctgtggtgcc aaggagtctc atctatctgc tgatgtccaa 1320
38 tacctgtctc atgtgtctc agagccctca tcaactccca tgccccatct cgactcccat 1380
39 ccccatctat ctgtggccct gagcatggct ctgccccag gtcgtcttgc acacctggc 1440
40 agccccctgt agttgacagg taagtgttag gcatgtagag caattgtccc aatgccactt 1500
41 gcttctcttc caagccgtcg aacagactgt gggatttgca gagtgtttct tccatgtctt 1560
42 tgaccacagg gtgtgtgtgc tgccaggctc tagatcacat ggcacagggc tggggcagag 1620
43 gcatagctat tgtctcgggc atccttccca ggggtgggtc ttacacaaat agaaggctct 1680
44 tgctctgagt tatgtgacgt gcctcagccc catggactaa gcaggggtct ggtataaaca 1740

Does Not Comply
Corrected Diskette Needed

PAGE: 2



RAW SEQUENCE LISTING
PATENT APPLICATION US/09/135,238A

DATE: 12/15/1999
TIME: 12:57:29

Input Set: I135238A.RAW

```

45      ctccctggaaa cgccttttgcc ctgatccaaa tgtttagcact tgctagtga cgtctactta 1800
46      tctcaagttc tatgctaaag gcaatttatc ttgatgtgat gataaaccaa acttattagc 1860
47      aagatatgca tatatatcca taaattctct ttactctgtc tccatccttt 1910
48      <210> SEQ ID NO 2
49      <211> LENGTH: 390
50      <212> TYPE: PRT
51      <213> ORGANISM: Homo sapiens
52      <400> SEQUENCE: 2
53      Met Asp Arg Trp Leu Trp Pro Leu Tyr Phe Leu Pro Val Ser Gly Ala
54      1 5 10 15
55      Leu Arg Ile Leu Pro Glu Val Lys Val Glu Gly Glu Leu Gly Gly Ser
56      20 25 30
57      Val Thr Ile Lys Cys Pro Leu Pro Glu Met His Val Arg Ile Tyr Leu
58      35 40 45
59      Cys Arg Glu Met Ala Gly Ser Gly Thr Cys Gly Thr Val Val Ser Thr
60      50 55 60
61      Thr Asn Phe Ile Lys Ala Glu Tyr Lys Gly Arg Val Thr Leu Lys Gln
62      65 70 75 80
63      Tyr Pro Arg Lys Asn Leu Phe Leu Val Glu Val Thr Gln Leu Thr Glu
64      85 90 95
65      Ser Asp Ser Gly Val Tyr Ala Cys Gly Ala Gly Met Asn Thr Asp Arg
66      100 105 110
67      Gly Lys Thr Gln Lys Val Thr Leu Asn Val His Ser Glu Tyr Glu Pro
68      115 120 125
69      Ser Trp Glu Glu Gln Pro Met Pro Glu Thr Pro Lys Trp Phe His Leu
70      130 135 140
71      Pro Tyr Leu Phe Gln Met Pro Ala Tyr Ala Ser Ser Ser Lys Phe Val
72      145 150 155 160
73      Thr Arg Val Thr Thr Pro Ala Gln Arg Gly Lys Val Pro Pro Val His
74      165 170 175
75      His Ser Ser Pro Thr Thr Gln Ile Thr His Arg Pro Arg Val Ser Arg
76      180 185 190
77      Ala Ser Ser Val Ala Gly Asp Lys Pro Arg Thr Phe Leu Pro Ser Thr
78      195 200 205
79      Thr Ala Ser Lys Ile Ser Ala Leu Glu Gly Leu Leu Lys Pro Gln Thr
80      210 215 220
81      Pro Ser Tyr Asn His His Thr Arg Leu His Arg Gln Arg Ala Leu Asp
82      225 230 235 240
83      Tyr Gly Ser Gln Ser Gly Arg Glu Gly Gln Gly Phe His Ile Leu Ile
84      245 250 255
85      Pro Thr Ile Leu Gly Leu Phe Leu Leu Ala Leu Leu Gly Leu Val Val
86      260 265 270
87      Lys Arg Ala Val Glu Arg Arg Lys Ala Leu Ser Arg Arg Ala Arg Arg
88      275 280 285
89      Leu Ala Val Arg Met Arg Ala Leu Glu Ser Ser Gln Arg Pro Arg Gly
90      290 295 300
91      Ser Pro Arg Pro Arg Ser Gln Asn Asn Ile Tyr Ser Ala Cys Pro Arg
92      305 310 315 320
93      Arg Ala Arg Gly Ala Asp Ala Ala Gly Thr Gly Glu Ala Pro Val Pro
94      325 330 335

```

PAGE: 3

 RAW SEQUENCE LISTING
 PATENT APPLICATION US/09/135,238A

 DATE: 12/15/1999
 TIME: 12:57:29

Input Set: I135238A.RAW

```

95      Gly Pro Gly Ala Pro Leu Pro Pro Ala Pro Leu Gln Val Ser Glu Ser
96              340                      345                      350
97      Pro Trp Leu His Ala Pro Ser Leu Lys Thr Ser Cys Glu Tyr Val Ser
98              355                      360                      365
99      Leu Tyr His Gln Pro Ala Ala Met Met Glu Asp Ser Asp Ser Asp Asp
100             370                      375                      380
101      Tyr Ile Asn Val Pro Ala
102             385                      390
103      <210> SEQ ID NO 3
104      <211> LENGTH: 73
105      <212> TYPE: PRT
106      <213> ORGANISM: Homo sapiens
107      <400> SEQUENCE: 3
108      Val Thr Ile Lys Cys Pro Leu Pro Glu Met His Val Arg Ile Tyr Leu
109              1                      5                      10                      15
110      Cys Arg Glu Met Ala Gly Ser Gly Thr Cys Gly Thr Val Val Ser Thr
111              20                      25                      30
112      Thr Asn Phe Ile Lys Ala Glu Trp Lys Gly Arg Val Thr Leu Lys Gln
113              35                      40                      45
114      Tyr Pro Arg Lys Asn Leu Phe Leu Val Glu Val Thr Gln Leu Thr Glu
115              50                      55                      60
116      Ser Asp Ser Gly Val Tyr Ala Cys Gly
117              65                      70
118      <210> SEQ ID NO 4
119      <211> LENGTH: 79
120      <212> TYPE: PRT
121      <213> ORGANISM: Homo sapiens
122      <400> SEQUENCE: 4
123      Leu Ser Leu Thr Cys Thr Val Ser Gly Ser Thr Phe Ser Asn Asp Tyr
124              1                      5                      10                      15
125      Tyr Thr Trp Val Arg Gln Pro Pro Gly Arg Gly Leu Glu Trp Ile Gly
126              20                      25                      30
127      Tyr Val Phe Tyr His Gly Thr Ser Asp Asp Thr Thr Pro Leu Arg Ser
128              35                      40                      45
129      Arg Val Thr Met Leu Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Arg
130              50                      55                      60
131      Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
132              65                      70                      75
133      <210> SEQ ID NO 5
134      <211> LENGTH: 73
135      <212> TYPE: PRT
136      <213> ORGANISM: Homo sapiens
137      <400> SEQUENCE: 5
138      Val Thr Leu Thr Cys Arg Ser Ser Thr Gly Ala Val Thr Thr Ser Asn
139              1                      5                      10                      15
140      Tyr Ala Asn Trp Val Gln Gln Lys Pro Asp His Leu Phe Thr Gly Ile
141              20                      25                      30
142      Gly Gly Thr Asn Asn Arg Ala Pro Gly Val Pro Ala Arg Phe Ser Gly
143              35                      40                      45
144      Ser Leu Ile Gly Asn Lys Ala Ala Leu Thr Ile Thr Gly Ala Gln Thr

```


PAGE: 4

RAW SEQUENCE LISTING
PATENT APPLICATION US/09/135,238A

DATE: 12/15/1999
TIME: 12:57:29

Input Set: I135238A.RAW

```

145          50          55          60
146      Glu Asp Glu Ala Ile Tyr Phe Cys Ala
147          65          70
148  <210> SEQ ID NO 6
149  <211> LENGTH: 72
150  <212> TYPE: PRT
151  <213> ORGANISM: Homo sapiens
152  <400> SEQUENCE: 6
153      Thr Ser Leu Asn Cys Thr Phe Ser Asp Ser Ala Ser Gln Tyr Phe Trp
154          1          5          10          15
155      Trp Tyr Arg Gln His Ser Gly Lys Ala Pro Lys Ala Leu Met Ser Ile
156          20          25          30
157      Phe Ser Asn Gly Glu Lys Glu Glu Gly Arg Phe Thr Ile His Leu Asn
158          35          40          45
159      Lys Ala Ser Leu His Phe Ser Leu His Ile Arg Asp Ser Gln Pro Ser
160          50          55          60
161      Asp Ser Ala Leu Tyr Leu Cys Ala
162          65          70
163  <210> SEQ ID NO 7
164  <211> LENGTH: 75
165  <212> TYPE: PRT
166  <213> ORGANISM: Homo sapiens
167  <400> SEQUENCE: 7
168      Val Thr Leu Arg Cys Lys Pro Ile Ser Gly His Asn Ser Leu Phe Trp
169          1          5          10          15
170      Tyr Arg Gln Thr Met Met Arg Gly Leu Leu Leu Ile Tyr Phe Asn
171          20          25          30
172      Asn Asn Val Pro Ile Asp Asp Ser Gly Met Pro Glu Asp Arg Phe Ser
173          35          40          45
174      Ala Lys Met Pro Asn Ala Ser Phe Ser Thr Leu Lys Ile Gln Pro Ser
175          50          55          60
176      Glu Pro Arg Asp Ser Ala Val Tyr Phe Cys Ala
177          65          70          75
178  <210> SEQ ID NO 8
179  <211> LENGTH: 74
180  <212> TYPE: PRT
181  <213> ORGANISM: Homo sapiens
182  <400> SEQUENCE: 8
183      Val Glu Leu Thr Cys Thr Ala Ser Gln Lys Lys Ser Ile Gln Phe His
184          1          5          10          15
185      Trp Lys Asn Ser Asn Gln Ile Lys Ile Leu Gly Asn Gln Gly Ser Phe
186          20          25          30
187      Leu Thr Lys Gly Pro Ser Lys Leu Asn Asp Arg Ala Asp Ser Arg Arg
188          35          40          45
189      Ser Leu Trp Asp Gln Gly Asn Phe Pro Leu Ile Ile Lys Asn Leu Lys
190          50          55          60
191      Ile Glu Asp Ser Asp Thr Tyr Ile Cys Glu
192          65          70
193  <210> SEQ ID NO 9
194  <211> LENGTH: 80

```

PAGE: 5

RAW SEQUENCE LISTING
PATENT APPLICATION US/09/135,238A

 DATE: 12/15/1999
 TIME: 12:57:29

Input Set: I135238A.RAW

195 <212> TYPE: PRT
 196 <213> ORGANISM: Homo sapiens
 197 <400> SEQUENCE: 9
 198 Ala Lys Met Ser Cys Glu Ala Lys Thr Phe Pro Lys Gly Thr Thr Ile
 199 1 5 10 15
 200 Tyr Trp Leu Arg Glu Leu Gln Asp Ser Asn Lys Asn Lys His Phe Glu
 201 20 25 30
 202 Phe Leu Ala Ser Arg Thr Ser Thr Lys Gly Ile Lys Tyr Gly Glu Arg
 203 35 40 45
 204 Val Lys Lys Asn Met Thr Leu Ser Phe Asn Ser Thr Leu Pro Phe Leu
 205 50 55 60
 206 Lys Ile Met Asp Val Lys Pro Glu Asp Ser Gly Phe Tyr Phe Cys Ala
 207 65 70 75 80

208 <210> SEQ ID NO 10
 209 <211> LENGTH: 76
 210 <212> TYPE: PRT
 211 <213> ORGANISM: Homo sapiens
 212 <400> SEQUENCE: 10
 213 Val Thr Ile Thr Cys Pro Phe Thr Tyr Ala Thr Arg Gln Leu Lys Lys
 214 1 5 10 15
 215 Ser Phe Tyr Lys Val Glu Asp Gly Glu Leu Val Leu Ile Ile Asp Ser
 216 20 25 30
 217 Ser Ser Lys Glu Ala Lys Asp Pro Arg Tyr Lys Gly Arg Ile Thr Leu
 218 35 40 45
 219 Gln Ile Gln Ser Thr Thr Ala Lys Glu Phe Thr Val Thr Leu Lys His
 220 50 55 60
 221 Leu Gln Leu Asn Asp Ala Gly Gln Tyr Val Cys Gln
 222 65 70 75

223 <210> SEQ ID NO 11
 224 <211> LENGTH: 84
 225 <212> TYPE: PRT
 226 <213> ORGANISM: Unknown
 227 <220> FEATURE:
 228 <221> NAME/KEY: UNSURE
 229 <222> LOCATION: (53)

230 <223> OTHER INFORMATION: The x at position 53 can represent either
 231 Phenylalanine, Valine or Isoleucine.

232 <220> FEATURE: Phenylalanine

233 <221> NAME/KEY: UNSURE

234 <222> LOCATION: (79)

235 <223> OTHER INFORMATION: The x at position 79 can represent either Alanine
 236 or Glycine.

237 <220> FEATURE:

238 <223> OTHER INFORMATION: Description of Unknown Organism: Consensus

239 <400> SEQUENCE: 11

W--> 240 Val Thr Leu Thr Cys Xaa Xaa Ser Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
 241 1 5 10 15
 W--> 242 Xaa Xaa Phe Xaa Trp Xaa Arg Gln Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
 243 20 25 30
 W--> 244 Leu Xaa Xaa Tyr Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa

all Xaa
 need
 explanation

see
 item 10
 on Error
 summary
 sheet

FYI

Please Note:

Use of n and/or Xaa have been detected in the Sequence Listing. Please review the Sequence Listing to ensure that a corresponding explanation is presented in the <220> to <223> fields of each sequence which presents at least one n or Xaa.

Input Set: I135238A.RAW

Line ? Error/Warning

Original Text

240 W "N" or "Xaa" used: Feature required

Val Thr Leu Thr Cys Xaa Xaa Ser Xaa Xaa X

242 W "N" or "Xaa" used: Feature required

Xaa Xaa Phe Xaa Trp Xaa Arg Gln Xaa Xaa X

244 W "N" or "Xaa" used: Feature required

Leu Xaa Xaa Tyr Xaa Xaa Xaa Xaa Xaa Xaa X

246 W "N" or "Xaa" used: Feature required

Tyr Xaa Xaa Arg Xaa Xaa Xaa Xaa Xaa Xaa X

248 W "N" or "Xaa" used: Feature required

Xaa Phe Ser Leu Thr Ile Xaa Asn Xaa Xaa X

250 W "N" or "Xaa" used: Feature required

Tyr Xaa Cys Ala